The SHARP trial investigated the efficacy (usefulness) of the oral multikinase inhibitor sorafenib (Nexavar) in the treatment of hepatocellular carcinoma.
Continue reading "SHARP Trial (Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol)"
